Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




LAMP Accurately Screens for Malaria in Pregnancy

By LabMedica International staff writers
Posted on 23 Jul 2018
Pregnant women are especially susceptible to Plasmodium infections and have the risk of developing severe disease and birth complications. These might include maternal anemia, intra-uterine growth retardation, infant low birth weight, prematurity, miscarriage and stillbirth.

Pregnant women frequently show low-density Plasmodium infections that require more sensitive methods for accurate diagnosis and early treatment of malaria. This is particularly relevant in low-malaria transmission areas, where intermittent preventive treatment is not recommended.

Scientists at the Universidad de Antioquia (Medellín, Colombia) and their international colleagues carried out a nested prospective study that used data and samples from a larger cross-sectional project conducted from May 2016 to January 2017 in three Colombian endemic areas. A total of 531 peripheral and placental samples were collected from pregnant women self-presenting at local hospitals for antenatal care visits, at delivery or seeking medical care for suspected malaria.

Blood samples were analyzed for Plasmodium parasites by light microscopy (LM), rapid diagnostic test (RDT) and loop mediated isothermal amplification (LAMP). The team used RDT SD Bioline Malaria antigen Pf/Pv as it can distinguish between P. falciparum, P. vivax and mixed infections. The commercially available Loopamp MALARIA Pan/Pf detection kit consists of reaction tubes with ready-made vacuum-dried reagents for the detection of P. falciparum (Pf-LAMP) or Plasmodium spp. (Pan-LAMP). DNA was extracted from half blood-spot filters and processed for a universal polymerase chain reaction (PCR) followed by nested species-specific PCR (nPCR) to detect the 18S ribosomal gene of P. falciparum, P. vivax and P. malariae.

The team reported that in peripheral samples, LAMP showed an improved sensitivity of 100% when compared with LM 79.5% and RDT 76.9%, particularly in afebrile women, for which LAMP sensitivity was, two-times higher than LM and RDT. Overall agreement among LAMP and nPCR was high. In placental blood, LAMP evidenced a four-fold improvement in sensitivity (88.9%) when compared with LM and RDT (22.2%), being the only method, together with nPCR, able to detect placental infections in peripheral blood.

The authors concluded that LAMP is a simple, rapid and accurate molecular tool for detecting gestational and placental malaria, being able to overcome the limited sensitivity of LM and RDT. These findings could guide maternal health programs in low-transmission settings to integrate LAMP in their surveillance systems for the active detection of low-density infections and asymptomatic malaria cases. The study was published on July 13, 2018, in the Malaria Journal.

Related Links:
Universidad de Antioquia


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.